175 filings
Page 3 of 9
6-K
pkv5w5a9t1kp0m9vm8
29 Jun 22
Current report (foreign)
4:30pm
6-K
43hbd
22 Jun 22
Current report (foreign)
5:00pm
6-K
a0snbi
17 Jun 22
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
4:15pm
6-K
8npwrub5dwf opy
17 May 22
Current report (foreign)
9:08am
6-K
zlfe39
17 May 22
Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results
8:20am
6-K
nppd2ewgjzv8myuak
17 May 22
Galmed updates business and clinical development strategy to better leverage Aramchol’s anti-fibrotic effects
7:51am
6-K
feiibr fyvmntlzpg7l
2 May 22
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial
7:07am
6-K
h3lr0ot 8kxak2k
28 Apr 22
Current report (foreign)
8:04am
6-K
wu3gim9stegh47x7
3 Mar 22
Current report (foreign)
5:16pm
6-K
2t0exzuj3yw9
11 Jan 22
Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt
8:15am
6-K
qa0f6l9 pll3oa
10 Jan 22
Galmed announces positive results of Phase 1 study of Amilo-5MER
8:11am
6-K
656qiz9x
8 Nov 21
Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results
8:25am
6-K
zvdxe9mg kxm
1 Nov 21
Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study
10:23am
6-K
3qv2ma8er vvs
12 Oct 21
Results of Galmed’s Phase 2b ARREST Trial of Aramchol Published in Nature Medicine
7:00am
6-K
gevu6tg
31 Aug 21
Current report (foreign)
4:30pm
6-K
5u57pwmqmwjy rebkw
23 Aug 21
Current report (foreign)
4:30pm
6-K
a7ypqkz4
19 Aug 21
Galmed Pharmaceuticals Announces Publication in “The Journal of Autoimmunity” for its IND ready, Amilo-5MER, a specific anti-inflammatory compound
8:11am
6-K
aq7 8h7jlhn
16 Aug 21
MHRA Agrees with Galmed’s Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study
8:31am
6-K
l1s8srgd0
5 Aug 21
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
7:00am
6-K
g5euqyf43
2 Aug 21
FDA Agrees with Galmed’s Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study
7:47am